{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:05:44Z","timestamp":1793379944357,"version":"4.5.0"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Cancer vaccines represent a promising strategy in cancer immunotherapy by inducing tumour-specific immune responses. However, their clinical efficacy remains limited due to challenges in antigen selection, including the distinction between self and non-self-antigens, as well as issues related to antigen delivery, immune activation, and tumour immune evasion. Advances in nanotechnology have introduced innovative approaches to improve vaccine stability, targeted delivery, and immunogenicity. Nanoparticle-based platforms, including lipid, polymeric, inorganic nanoparticles, and virus-like particles, enable efficient delivery of tumour antigens and immunostimulatory adjuvants to antigen-presenting cells, thereby enhancing adaptive immune responses. Despite these advances, several translational challenges persist, including immunosuppressive tumour microenvironments, inefficient lymph node targeting, safety concerns, and manufacturing limitations. This review summarizes key nanoparticle platforms used in cancer vaccine development and discusses major barriers to their clinical translation. We also emphasize platform-selection criteria, cargo-dependent carrier design, nanoparticle size constraints, engineering strategies used to improve cytosolic delivery and endosomal escape, and the current clinical pipeline of cancer nanovaccines. Additionally, emerging strategies such as personalized nanovaccines, mRNA vaccine platforms, and combination immunotherapies are highlighted as promising approaches to improve therapeutic efficacy. These advances are expected to accelerate the clinical translation of nanotechnology-enabled cancer vaccines and support the development of next-generation cancer immunotherapies.<\/jats:p>","DOI":"10.3390\/vaccines14060463","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:17:09Z","timestamp":1779441429000},"page":"463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nanotechnology-Based Cancer Vaccines: Translational Barriers and Emerging Strategies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8603-0486","authenticated-orcid":false,"given":"Muneera","family":"Anwer","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2425-0365","authenticated-orcid":false,"given":"Rifat","family":"Rahman","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, QLD 4215, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"117766","DOI":"10.1016\/j.biopha.2024.117766","article-title":"Bacterial ghosts: A breakthrough approach to cancer vaccination","volume":"182","author":"Anwer","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.trecan.2017.12.007","article-title":"Re-emergence of dendritic cell vaccines for cancer treatment","volume":"4","author":"Saxena","year":"2018","journal-title":"Trends Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"16204","DOI":"10.1021\/acsnano.4c15765","article-title":"Cancer nanovaccines: Mechanisms, design principles, and clinical translation","volume":"19","author":"Zaccariotto","year":"2025","journal-title":"ACS Nano"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"He, J., Xiao, W., Hua, D., Liu, M., Guo, H., Xu, L., Xiao, M., Du, Y., and Li, J. (2025). Nanovaccines: Innovative Advances from Design Strategies to Clinical Translation. Vaccines, 13.","DOI":"10.3390\/vaccines13090900"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12951-023-01977-1","article-title":"Targeting lymph node delivery with nanovaccines for cancer immunotherapy: Recent advances and future directions","volume":"21","author":"Li","year":"2023","journal-title":"J. Nanobiotechnology"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lin, Y., Chen, X., Wang, K., Liang, L., and Zhang, H. (2024). An overview of nanoparticle-based delivery platforms for mRNA vaccines for treating cancer. Vaccines, 12.","DOI":"10.3390\/vaccines12070727"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13045-024-01628-4","article-title":"Personalized nanovaccines for treating solid cancer metastases","volume":"17","author":"Feng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","article-title":"Enhancing cancer immunotherapy with nanomedicine","volume":"20","author":"Irvine","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines\u2014A new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1039\/D2MH01358D","article-title":"Polymeric nanoparticle-based nanovaccines for cancer immunotherapy","volume":"10","author":"Zhang","year":"2023","journal-title":"Mater. Horiz."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Chen, C., Xu, Y., Meng, H., Bao, H., Hu, Y., Li, C., and Xia, D. (2025). Nano-oncologic vaccine for boosting cancer immunotherapy: The horizons in cancer treatment. Nanomaterials, 15.","DOI":"10.3390\/nano15020122"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"14935","DOI":"10.2147\/IJN.S565558","article-title":"Key Clinical Frontiers of mRNA Loaded Lipid Nanoparticles in Cancer Vaccines","volume":"20","author":"Cao","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Ning, W., Yan, S., Song, Y., Xu, H., Zhang, J., and Wang, X. (2025). Virus-like particle: A nano-platform that delivers cancer antigens to elicit an anti-tumor immune response. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1504124"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12951-024-02758-0","article-title":"Tailoring biomaterials for vaccine delivery","volume":"22","author":"Zhuo","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"ref_18","first-page":"100400","article-title":"Breaking hypoxic barrier: Oxygen-supplied nanomaterials for enhanced T cell-mediated tumor immunotherapy","volume":"10","author":"Xiang","year":"2025","journal-title":"Int. J. Pharm. X"},{"key":"ref_19","first-page":"30","article-title":"Engineered Cancer Nanovaccines: A New Frontier in Cancer Therapy","volume":"17","author":"Wang","year":"2024","journal-title":"Nanomicro Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101068","DOI":"10.1016\/j.mtbio.2024.101068","article-title":"Targeting lymph nodes for enhanced cancer vaccination: From nanotechnology to tissue engineering","volume":"26","author":"Wang","year":"2024","journal-title":"Mater. Today Bio"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41392-024-01889-y","article-title":"Current advance of nanotechnology in diagnosis and treatment for malignant tumors","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_22","first-page":"101166","article-title":"Nanovaccines in cancer immunoprevention and immunotherapy: Current insights and future directions","volume":"47","author":"Uti","year":"2026","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Delgado-Almenta, V., Blaya-C\u00e1novas, J.L., Calahorra, J., L\u00f3pez-Tejada, A., Gri\u00f1\u00e1n-Lis\u00f3n, C., and Granados-Principal, S. (2025). Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17020216"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.accounts.1c00544","article-title":"Chemistry of lipid nanoparticles for RNA delivery","volume":"55","author":"Eygeris","year":"2021","journal-title":"Acc. Chem. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"102365","DOI":"10.1016\/j.nantod.2024.102365","article-title":"Co-delivery of STING and TLR7\/8 agonists in antigen-based nanocapsules to dendritic cells enhances CD8+ T cell-mediated melanoma remission","volume":"57","author":"Schunke","year":"2024","journal-title":"Nano Today"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., and Hua, S. (2015). Advances and challenges of liposome assisted drug delivery. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00286"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2401631","DOI":"10.1002\/smll.202401631","article-title":"Cancer Nanovaccines: Nanomaterials and Clinical Perspectives","volume":"20","author":"Desai","year":"2024","journal-title":"Small"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1038\/s43018-024-00850-w","article-title":"Personalized neoantigen therapy for melanoma immunotherapy","volume":"5","author":"Danelli","year":"2024","journal-title":"Nat. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"ref_33","first-page":"100484","article-title":"Recent advances in lipid nanoparticles for cancer vaccine delivery: Challenges and future perspectives","volume":"11","author":"Hasan","year":"2026","journal-title":"Int. J. Pharm. X"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"126263","DOI":"10.1016\/j.ijpharm.2025.126263","article-title":"Endosomal escape and current obstacles in ionizable lipid nanoparticles mediated gene delivery: Lessons from COVID-19 vaccines","volume":"685","author":"Meerasa","year":"2025","journal-title":"Int. J. Pharm."},{"key":"ref_35","first-page":"270","article-title":"Nanoparticles in cancer therapy: Strategies to penetrate and modulate the tumor microenvironment\u2014A review","volume":"6","author":"Hoang","year":"2025","journal-title":"Smart Mater. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: A phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Elfatimi, E., Lekbach, Y., Prakash, S., and BenMohamed, L. (2025). Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics\u2014Yesterday, today, and tomorrow. Front. Artif. Intell., 8.","DOI":"10.3389\/frai.2025.1620572"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kong, H. (2025). Advances in Personalized Cancer Vaccine Development: AI Applications from Neoantigen Discovery to mRNA Formulation. BioChem, 5.","DOI":"10.3390\/biochem5020005"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1002355","DOI":"10.37349\/etat.2025.1002355","article-title":"Next-generation nanocarriers for precision antitumor therapy: From passive targeting to intelligent response","volume":"6","author":"Singh","year":"2025","journal-title":"Explor. Target. Antitumor Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jconrel.2012.05.042","article-title":"Challenges in design of translational nanocarriers","volume":"164","author":"Sun","year":"2012","journal-title":"J. Control Release"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105068","DOI":"10.1016\/j.critrevonc.2025.105068","article-title":"The role of therapeutic cancer vaccines in the modern immunotherapy era: State of the art with recent progress and future challenges","volume":"217","author":"Rota","year":"2026","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12668-025-01980-w","article-title":"Artificial Intelligence-Assisted Design of Nanomedicines for Breast Cancer Diagnosis and Therapy: Advances, Challenges, and Future Directions","volume":"15","author":"Shirzad","year":"2025","journal-title":"BioNanoScience"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T09:40:48Z","timestamp":1779442848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/6\/463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["vaccines14060463"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14060463","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]}}}